Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 4/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427290 | 0.77 | NOTUM (0.54) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL23486492 | 0.77 | NOTUM (0.54) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL14873776 | 0.77 | NOTUM (0.54) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL6916688 | 0.77 | MEN1 (0.37) | ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL23088294 | 0.75 | NOTUM (0.51) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL23088219 | 0.75 | NOTUM (0.51) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL29792599 | 0.75 | NOTUM (0.51) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL23747894 | 0.73 | NOTUM (0.50) | NOTUMF2ALDH1A1KMT2ANPSR1 | |
| SCHEMBL16132838 | 0.73 | NOTUM (0.50) | NOTUMF2ALDH1A1KMT2AKDM4E | |
| SCHEMBL15562531 | 0.73 | NOTUM (0.50) | NOTUMF2ALDH1A1NPSR1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-17 | — | — | US | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| EP-3863713-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| CN-112839711-A | Phenyltetrazole derivatives as plasma kallikrein inhibitors | 勃林格殷格翰国际有限公司 | 2021-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | NOTUM 1872/4885F2 28/4885ALDH1A1 1253/4885 |
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | KLKB1, SERPINE1, SERPINB1 | NOTUM 1872/4885F2 28/4885ALDH1A1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.